Company Profile
Aurinia Pharmaceuticals Inc Stock Price, News & Analysis
- Ticker:
- AUPH
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Canada
Stock performance
16.13 USD (+6.19%)
Close
Last updated: August 6, 2026
1.98B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AUPH closed up 6.19% at $16.13. No new same-company headline was identified in the current news window.
Company overview
Business overview
Aurinia Pharmaceuticals is a biopharmaceutical company focused on autoimmune disease, especially kidney-related immune disorders. Its story combines commercial products with the challenge of maintaining growth in a specialty immunology market.
Geographic Base and Sector Classification
Aurinia is headquartered in Canada and listed on NASDAQ. It sits in specialty biopharma with immunology and renal exposure.
Business Model Characteristics
The company depends on product sales, market access, and the ability to manage a focused franchise in autoimmune disease. Investors watch revenue, label strategy, and pipeline or portfolio updates.
Position Within the Biotechnology Landscape
Aurinia occupies a durable specialty-immunology niche within biotech. It has commercial grounding, but the stock remains sensitive to execution and franchise durability.
Future catalysts
Aurinia’s catalysts are Lupkynis execution, lupus-nephritis adoption, and any label or commercial update that broadens the franchise. The market will care about whether growth stays steady.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aurinia Pharmaceuticals Inc (AUPH)?
Aurinia Pharmaceuticals Inc (AUPH) most recently closed at 16.13 USD, a +6.19% move versus the previous session.
What is the market cap of Aurinia Pharmaceuticals Inc (AUPH)?
Aurinia Pharmaceuticals Inc currently has a market capitalization of 1.98B USD on BioPharmSignal.
What does Aurinia Pharmaceuticals Inc do?
Aurinia Pharmaceuticals is a biopharmaceutical company focused on autoimmune disease, especially kidney-related immune disorders. Its story combines commercial products with the challenge of maintaining growth in a specialty immunology market.
On which exchange is AUPH stock listed?
Aurinia Pharmaceuticals Inc (AUPH) is associated with NASDAQ, Canada, Biopharma.
What is Aurinia?
Aurinia’s catalysts are Lupkynis execution, lupus-nephritis adoption, and any label or commercial update that broadens the franchise.
Which conditions is Aurinia Pharmaceuticals Inc targeting with Aurinia?
Aurinia Pharmaceuticals Inc is associated with immunology based on its company overview and current catalyst commentary.
How does Aurinia Pharmaceuticals Inc describe recent progress with Aurinia?
Aurinia’s catalysts are Lupkynis execution, lupus-nephritis adoption, and any label or commercial update that broadens the franchise.
What is Pharmaceuticals?
Aurinia Pharmaceuticals is a biopharmaceutical company focused on autoimmune disease, especially kidney-related immune disorders.